Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.
Non Small Cell Lung Cancer|Non-squamous Non-small-cell Lung Cancer|Urothelial Carcinoma|Malignant Mesothelioma
DRUG: Cabozantinib|DRUG: Pemetrexed
Assess the maximum tolerated dose (MTD) of cabozantinib in combination with pemetrexed, Dose-limiting toxicity of grade 3 or higher using CTCAE 5, 4 weeks or 28 days assessment.
Assess objective response rate (RR), RR measured by Tumor response evaluation with RECIST, To be measured through study completion; an average of 1 year.|Progression-free survival (PFS), PFS measured from the time of study treatment to the date of progression., To be measured through study completion; an average of 1 year.|Overall survival (OS)., Measured from the time of start of treatment to time of death or time of last assessment., OS measured through study completion, and an average of 1 year
This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.